This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Stocks Set to Soar on Bullish Earnings

Bio-Reference Laboratories

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One potential earnings short-squeeze trade is health care facilities player Bio-Reference Laboratories (BRLI), which is set to release numbers on Thursday before the market open. This company is engaged in providing laboratory testing services to customers in the greater New York metropolitan area as well as in other states. Wall Street analysts, on average, expect Bio-Reference Laboratories to report revenue of $173.67 million on earnings of 43 cents per share.

If you're looking for a strong trending heavily-shorted healthcare stock ahead of its earnings report this week, then make sure to take a hard look at shares of Bio-Reference Laboratories. This stock has been on fire so far in 2012, with shares exploding higher by over 70%. As we get close to its earnings report, shares of BRLI are trending just three points off its 52-week high of $30.15 a share.

>>7 Stocks Rising on Big Volume

The current short interest as a percentage of the float for Bio-Reference Laboratories is extremely high at 25.1%. That means that out of the 24.47 million shares in the tradable float, 6.13 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 2.6%, or by about 154,000 million shares. If the bears are pressing their luck in front of this quarter, and they end up being wrong, then we could easily see a monster short-squeeze since this company's float is very small.

From a technical perspective, BRLI is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending very strong for the last three months, with shares exploding higher from a low of $18.29 to its recent high of $30.15 a share. During that sharp move higher, shares of BRLI have been mostly making higher lows and higher highs, which is bullish technical price action. That move has pushed BRLI within range of triggering a major breakout trade post-earnings.

If you're in the bull camp on BRLI, then I would wait until after they report earnings and look for long-biased trades if this stock holds its trend above $26.08 to its 50-day moving average of $26.75 a share with strong upside volume flows. I would consider any upside volume day that registers near or above its three-month average action of 241,020 shares as bullish. If BRLI can hold that trend, then this stock has a great chance of re-testing and possibly taking out its 52-week high of $30.15 a share post-earnings.

I would simply avoid BRLI or look for short-biased trades if after earnings the stock fails to hold that trend, and then takes out that major near-term support level at $26.08 a share with high volume. If we get that move, then BRLI will setup to re-test and possibly take out its next major support level at $24.58 a share post-earnings. It's possible that BRLI could drop back towards its 200-day moving average of $21.23 a share if those major support levels are taken out post-earnings.

5 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,965.29 +45.70 0.27%
S&P 500 1,984.40 +2.80 0.14%
NASDAQ 4,528.1310 +0.6170 0.01%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs